Assessment Of Management Strategies In Alcoholic Liver Disease Patients With Hypertension Or Diabetes Mellitus
DOI:
https://doi.org/10.63682/jns.v14i13S.4278Keywords:
Ursodeoxycholic acid, alcoholic liver disease, hypertension, Spironolactone, Rifaximin, human albuminAbstract
Objective: Analysis of different Treatment Strategies in ALD with Hypertension & ALD with Diabetes Mellitus and its Prescription Patterns Assessment with Comparison study of Alcoholic liver disease or Alcoholic Liver Disease with Hypertension or Diabetes Mellitus. To learn about the specific treatments given in patients of ALD
Methods: A retrospective observational analysis was conducted in a tertiary care center. The data of the patients undergoing treatment for ALD with hypertension or diabetes mellitus were obtained. Patients with ALD undergoing therapy. Data of 100 patients was gathered and examined from the Parul Sevashram Hospital. The data was reported and analyzed using graphical, chart, figures, and tabulations, and it was visually summarized in the data collection analysis form.
Results: Among 100 patients, 97% of patients were prescribed with oral ursodeoxycholic acid in both ALD with Hypertension & ALD with Diabetes mellitus. Furthermore, Oral Spironolactone was prescribed in 95% Patients for the treatment. And it was followed by Rifaximin & intravenous Human Albumin in some patients. It has also been noticed that oral Lactulose, intravenous Furosemide & various other supplements have been prescribed majorly in ALD alongside.
Conclusion: Ursodeoxycholic acid, which is an Hepatoprotective Agent, Spironolactone which is an Aldosterone receptor antagonist, Rifaximin which is an antibiotic are majorly used in the treatment of this ailment. However more research and large sample size is required for the assessment of management of the following.
Downloads
Metrics
References
Hussen N, Zhu L, Tetangco E, Ellison S. Hepatoptosis in a Patient with Alcoholic Hepatitis. Official journal of the American College of Gastroenterology| ACG. 2018 Nov 1;113(11):1581.
Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000Research. 2018;7.
Patel R, Mueller M. Alcoholic Liver Disease. [Updated 2023 Jul 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
Dugum M, McCullough A. Diagnosis and management of alcoholic liver disease. Journal of clinical and translational hepatology. 2015 Jun 6;3(2):109.
O'shea RS, Dasarathy S, McCullough AJ, Practice Guideline Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010 Jan;51(1):307-28.
Mayo-Smith MF, Beecher LH, Fischer TL, Gorelick DA, Guillaume JL, Hill A, Jara G, Kasser C, Melbourne J. Management of alcohol withdrawal delirium: an evidence-based practice guideline. Archives of internal medicine. 2004 Jul 12;164(13):1405-12.
Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008 Jul 1;32(5):1106-17.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
